omadacycline; amadacycline (Nuzyra)
Jump to navigation
Jump to search
Indications
- community-acquired pneumonia
- acute skin infections & skin structure infections
Dosage
- IV & oral once daily formulations
injection: 100 mg
tablet: 150 mg
Antimicrobial activity
- Streptococcus
- Streptococcus pneumoniae
- Streptococcus pyogenes
- Streptococcus anginosus group
- Streptococcus anginosus
- Streptococcus intermedius
- Streptococcusconstellatus
- Enterococcus faecalis
- Staphylococcus
- Staphylococcus aureus (MSSA)
- Staphylococcuslugdunensis
- Haemophilus influenzae & Haemophilus parainfluenzae
- Klebsiella pneumoniae
- Legionella pneumophila
- Mycoplasma pneumoniae
- Chlamydophila pneumoniae
- Enterobacter cloacae
Adverse effects
- nausea, vomiting, diarrhea, constipation
- infusion site reactions,
- elevated serum transaminsases
- elevated serum gamma-glutamyl transferase
- hypertension
- headache
- insomnia
Mechanism of action
More general terms
References
- ↑ Brooks M FDA Clears Omadacycline (Nuzyra) for Two Infections Medscape - Oct 03, 2018. https://www.medscape.com/viewarticle/902885
- ↑ Stets R, Popescu M, Gonong JR et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019 Feb 7; 380:517. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30726692 https://www.nejm.org/doi/10.1056/NEJMoa1800201
O'Riordan W, Green S, Overcash JS et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019 Feb 7; 380:528. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30726689 https://www.nejm.org/doi/10.1056/NEJMoa1800170
Chambers HF. Omadacycline - he newest tetracycline. N Engl J Med 2019 Feb 7; 380:588 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30726683 https://www.nejm.org/doi/10.1056/NEJMe1900188 - ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION NUZYRA (omadacycline) for injection, for intravenous use NUZYRA (omadacycline) tablets, for oral use https://www.nuzyra.com/PI.pdf